January 8, 2018 / 12:14 PM / a year ago

BRIEF-Regeneron Pharma Says Enter Letter Agreement Relating To Immuno-Oncology License,Collaboration Agreement With Sanofi

Jan 8 (Reuters) - Regeneron Pharmaceuticals Inc:

* REGENERON PHARMACEUTICALS-ON JAN 7,ENTERED LETTER AGREEMENT RELATING TO IMMUNO-ONCOLOGY LICENSE,COLLABORATION AGREEMENT WITH SANOFI BIOTECHNOLOGY SAS​

* REGENERON PHARMACEUTICALS-PURSUANT TO LETTER AGREEMENT, CO, SANOFI SAS, AGREED TO INCREASE REGN2810 BUDGET AMOUNT TO $1.640 BILLION

* REGENERON -ENTERED LETTER AGREEMENT ALSO RELATING TO AMONG OTHERS​, THE INVESTOR AGREEMENT DATED AS OF JAN 11, 2014, WITH SANOFI - SEC FILING

* REGENERON PHARMACEUTICALS INC - ‍ ALSO AGREED TO REVISE REGN2810 GLOBAL DEVELOPMENT PLAN AND REGN2810 GLOBAL DEVELOPMENT BUDGET Source text: [bit.ly/2qIaBGi] Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below